Status:
COMPLETED
Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.
Lead Sponsor:
AstraZeneca
Conditions:
Stage IIIB/IV
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the E...
Detailed Description
Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.
Eligibility Criteria
Inclusion
- Patients with confirmed diagnosis of lung adenocarcinoma, stage IIIb/IV.
- Patients under 1st line treatment against lung adenocarcinoma.
Exclusion
- Patients not having the information required by the protocol.
Key Trial Info
Start Date :
May 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2013
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT01525199
Start Date
May 1 2012
End Date
November 1 2013
Last Update
April 14 2014
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bahía Blanca, Buenos Aires, Argentina
2
Research Site
Ciudad de Buenos Aires, Buenos Aires, Argentina
3
Research Site
Junín, Buenos Aires, Argentina
4
Research Site
La Plata, Buenos Aires, Argentina